FDA Clears Heart Disease Trial at Harvard's Boston Children’s Hospital Using Mesoblast's Cell Therapy to Grow Heart Muscle in Children With Congenital Heart Disease
April 03, 2017 16:34 ET
|
Mesoblast Limited
BOSTON, NEW YORK, and MELBOURNE, Australia, April 03, 2017 (GLOBE NEWSWIRE) -- Boston Children’s Hospital, the pediatric teaching hospital of Harvard University, and Mesoblast Limited (ASX:MSB)...
Independent Data Monitoring Committee Initiates process for Interim Analysis of Mesoblast’s Phase 3 Chronic Heart Failure Trial
March 31, 2017 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, March 31, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the Independent Data Monitoring Committee (IDMC) for the...
Mesoblast Raises US$40 Million
March 27, 2017 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, March 27, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it has successfully completed a fully underwritten institutional...
Durable Three-Year Outcomes In Degenerative Disc Disease After a Single Injection of Mesoblast’s Cell Therapy
March 15, 2017 06:00 ET
|
Mesoblast Limited
MELBOURNE, Australia and NEW YORK, March 15, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced 36-month results from the randomized, placebo-controlled 100-patient...
FDA Grants Fast Track Designation for Mesoblast’s Cell Therapy in Children With Acute Graft Versus Host Disease
March 07, 2017 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, March 07, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the United States Food and Drug Administration (FDA) has...
Mesoblast Presents Corporate Update and Financial Results for the Half Year Period Ended December 31, 2016
February 26, 2017 17:07 ET
|
Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Feb. 26, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today provided the market with a strategic update, financial results for the...
Mesoblast to Host Second Quarter and First Half Financial Results Conference Call and Webcast
February 24, 2017 16:40 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the second quarter/half year ended...
Durable Responses and Sustained Low Disease Activity Over Nine Months After a Single Dose of Mesoblast Cell Therapy in Rheumatoid Arthritis Patients Resistant to Anti-TNF Agents
February 15, 2017 16:54 ET
|
Mesoblast Limited
Key points: A single intravenous infusion of Mesoblast's allogeneic "off-the-shelf" Mesenchymal Precursor Cells (MPCs) resulted in durable responses through nine months (39 weeks) in a 48-patient...
Published Study Results Show That Mesoblast Cells Administered Intravenously Significantly Ameliorate Joint Disease in Model of Early Rheumatoid Arthritis
February 13, 2017 06:00 ET
|
Mesoblast Limited
Study provides translational and mechanistic support for Phase 2 trial results of Mesoblast’s cell therapy in patients with biologic refractory rheumatoid arthritis MELBOURNE, Australia and NEW YORK,...
Mesoblast Director Recognized by Peers for Cardiovascular Leadership
January 31, 2017 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Jan. 31, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that its non-executive Director, Dr Eric A. Rose, was awarded the 2017...